CTOs on the Move

Eversana

www.eversana.com

 
EVERSANA™ is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion
  • www.eversana.com
  • 190 North Milwaukee Street
    Milwaukee, WI USA 53202
  • Phone: 414.299.4900

Executives

Name Title Contact Details
Ryan Sparks
Chief Information Officer Profile
Mark Henke
Chief Information Security Officer Profile
Scott Snyder
Chief Digital Officer Profile

Similar Companies

itsRX

itsRX is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axm Pharma

AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal

I.C.H. Corporation

I.C.H. Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

International Medication Systems

International Medication Systems is a South El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.